from the PYC ANN: Through collaborative efforts with Genentech...

from the PYC ANN: Through collaborative efforts with Genentech during the quarter, Phylogica has also delivered the antibacterial compound Temporin A. This serves as additional validation of the FPP platform and shows potential for the FPP platform to be utilised in the area of superbug antibiotics.

So with that in mind here is a link to a recent video interview with Genentech's Associate Director of Business Development. PYC aren't mentioned, but it's interesting from 1.55min to 2.10min MR states:
"We are heavily involved in cell internalization technologies. These are technologies that could fundamentally change a lot of the ways we look at targeting different therapeutic modalities."